Skip Navigation



Annals of Oncology Advance Access published online on February 2, 2005
Annals of Oncology, doi:10.1093/annonc/mdi071
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/3/513    most recent
mdi071v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tripathy, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tripathy, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter

Reply to "Letter to the Editor on ‘Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial"’, by A. M. Westermann doi:10.1093/annonc/mdi072

D. Tripathy 1*

1 University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, NC8.106, Dallas, TX 75390-8852, USA

* To whom correspondence should be addressed.
D. Tripathy, E-mail: debu.tripathy{at}utsouthwestern.edu



This article has no Abstract.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.